GlobeNewswire: Seelos Therapeutics, Inc. Contains the last 10 of 344 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:52:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/06/15/2048044/0/en/Seelos-Therapeutics-to-Host-Key-Opinion-Leader-Call-to-Discuss-Phase-I-Data-and-Upcoming-Trial-Design-for-SLS-002.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-0022020-06-15T12:01:00Z<![CDATA[NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD) during the call.]]>https://www.globenewswire.com/news-release/2020/05/28/2040094/0/en/Seelos-Therapeutics-Announces-Initiation-of-Preclinical-Study-of-SLS-004-in-Parkinson-s-Disease.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease2020-05-28T11:01:00Z<![CDATA[Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein Gene Therapy Program to Target the Regulation of the SNCA Gene of Alpha-Synuclein ]]>https://www.globenewswire.com/news-release/2020/05/19/2035716/0/en/Seelos-Therapeutics-to-Host-Key-Opinion-Leader-Call-to-Discuss-the-Unmet-Medical-Needs-in-Suicide-and-Depression.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics to Host Key Opinion Leader Call to Discuss the Unmet Medical Needs in Suicide and Depression2020-05-19T13:01:00Z<![CDATA[NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to discuss the unmet medical needs in suicide and depression on Tuesday, May 26, 2020 at 1:00 p.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2020/05/18/2034915/0/en/Seelos-Therapeutics-to-Participate-in-the-Benchmark-Healthcare-Virtual-Conference.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference2020-05-18T12:01:00Z<![CDATA[NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference, June 15-16, 2020.]]>https://www.globenewswire.com/news-release/2020/05/15/2034331/0/en/Seelos-Therapeutics-Announces-Appointment-of-Judith-Dunn-to-the-Board-of-Directors.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors2020-05-15T14:30:00Z<![CDATA[NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Judith Dunn, Ph.D. to its Board of Directors.]]>https://www.globenewswire.com/news-release/2020/05/15/2034166/0/en/Seelos-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-for-SLS-005-Trehalose-in-Sanfilippo-Syndrome.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome2020-05-15T11:30:00Z<![CDATA[NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Rare Pediatric Disease Designation (RPDD) for SLS-005 in Sanfilippo syndrome from the U.S. Food and Drug Administration (FDA).]]>https://www.globenewswire.com/news-release/2020/05/12/2031876/0/en/Seelos-Therapeutics-to-Participate-in-the-Jefferies-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference2020-05-12T12:01:00Z<![CDATA[NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Jefferies Virtual Healthcare Conference, June 2-4, 2020.]]>https://www.globenewswire.com/news-release/2020/05/04/2026712/0/en/Seelos-Therapeutics-Receives-Notice-of-Allowance-for-an-Additional-US-Patent-for-Trehalose-SLS-005.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) 2020-05-04T12:01:00Z<![CDATA[NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos' U.S. patent number 10,437,637 (application number 16/263,707) titled “COMPOSITIONS AND METHODS FOR TREATING AN AGGREGATION DISEASE OR DISORDER” for trehalose (SLS-005).]]>https://www.globenewswire.com/news-release/2020/04/30/2025612/0/en/Seelos-Therapeutics-Receives-Orphan-Drug-Designation-for-SLS-005-Trehalose-in-Sanfilippo-Syndrome.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics Receives Orphan Drug Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome2020-04-30T17:31:00Z<![CDATA[NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has been granted Orphan Drug Designation (ODD) for SLS-005 in Sanfilippo syndrome from U.S. Food and Drug Administration (FDA).]]>https://www.globenewswire.com/news-release/2020/04/08/2013636/0/en/Seelos-Therapeutics-Provides-Q1-2020-Business-Update-and-Pipeline-Developments.html?f=22&fvtc=4&fvtv=11966Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments2020-04-08T13:01:00Z<![CDATA[NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provides its first quarter business update and pipeline developments.]]>